Pathogenic stromal cells as therapeutic targets in joint inflammation

[1]  J. Pollard,et al.  Erythro-myeloid progenitors contribute endothelial cells to blood vessels , 2018, Nature.

[2]  C. Buckley,et al.  Leukocyte trafficking between stromal compartments: lessons from rheumatoid arthritis , 2018, Nature Reviews Rheumatology.

[3]  C. Buckley,et al.  Stroma: the forgotten cells of innate immune memory , 2018, Clinical and experimental immunology.

[4]  D. Winter,et al.  Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound‐Guided Synovial Biopsies in Rheumatoid Arthritis , 2018, Arthritis & rheumatology.

[5]  C. Prati,et al.  Microvascular endothelial dysfunction in rheumatoid arthritis , 2018, Nature Reviews Rheumatology.

[6]  S. Gay,et al.  Analysis of early changes in DNA methylation in synovial fibroblasts of RA patients before diagnosis , 2018, Scientific Reports.

[7]  M. Feldmann,et al.  Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to GAlert , 2018, Proceedings of the National Academy of Sciences.

[8]  Nir Hacohen,et al.  Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis , 2018, Nature Communications.

[9]  R. Darnell,et al.  Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation , 2018, Nature Communications.

[10]  T. Huizinga,et al.  The B cell response to citrullinated antigens in the development of rheumatoid arthritis , 2018, Nature Reviews Rheumatology.

[11]  Robert A. Weinberg,et al.  EMT in cancer , 2018, Nature Reviews Cancer.

[12]  E. Schwarz,et al.  Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis , 2018, Nature Reviews Rheumatology.

[13]  Steffen Jung.  Macrophages and monocytes in 2017: Macrophages and monocytes: of tortoises and hares , 2018, Nature Reviews Immunology.

[14]  C. Serhan.  Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. , 2017, Molecular aspects of medicine.

[15]  B. Marsden,et al.  Mapping tenascin-C interaction with toll-like receptor 4 reveals a new subset of endogenous inflammatory triggers , 2017, Nature Communications.

[16]  C. Ospelt.  Synovial fibroblasts in 2017 , 2017, RMD Open.

[17]  E. Ballestar,et al.  New insights into the epigenetics of inflammatory rheumatic diseases , 2017, Nature Reviews Rheumatology.

[18]  S. Dakin,et al.  Increased 15-PGDH expression leads to dysregulated resolution responses in stromal cells from patients with chronic tendinopathy , 2017, Scientific Reports.

[19]  R. Gay,et al.  The epigenetic architecture at gene promoters determines cell type-specific LPS tolerance. , 2017, Journal of autoimmunity.

[20]  Andrew Filer,et al.  Identification of a transitional fibroblast function in very early rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[21]  P. Tak,et al.  Stromal cell markers are differentially expressed in the synovial tissue of patients with early arthritis , 2017, PloS one.

[22]  C. Serhan,et al.  A cluster of immunoresolvents links coagulation to innate host defense in human blood , 2017, Science Signaling.

[23]  G. Ateshian,et al.  Fibroblast-like synoviocyte mechanosensitivity to fluid shear is modulated by interleukin-1α. , 2017, Journal of biomechanics.

[24]  P. Tak,et al.  Synovial tissue research: a state-of-the-art review , 2017, Nature Reviews Rheumatology.

[25]  C. Ospelt,et al.  Why location matters — site-specific factors in rheumatic diseases , 2017, Nature Reviews Rheumatology.

[26]  W. Robinson,et al.  Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis , 2017, Science Immunology.

[27]  G. Kollias,et al.  Epigenetically-driven anatomical diversity of synovial fibroblasts guides joint-specific fibroblast functions , 2017, Nature Communications.

[28]  S. Gay,et al.  Epigenetics in the pathogenesis of RA , 2017, Seminars in Immunopathology.

[29]  Lenka Munoz,et al.  Non-kinase targets of protein kinase inhibitors , 2017, Nature Reviews Drug Discovery.

[30]  Kevin Wei,et al.  Autocrine Loop Involving IL‐6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production of Inflammatory Mediators , 2017, Immunity.

[31]  D. M. van der Heijde,et al.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis , 2017, The New England journal of medicine.

[32]  A. Filer,et al.  Priming in response to pro-inflammatory cytokines is a feature of adult synovial but not dermal fibroblasts , 2017, Arthritis Research & Therapy.

[33]  G. Murrell,et al.  Inflammatory mechanisms in tendinopathy – towards translation , 2017, Nature Reviews Rheumatology.

[34]  M. Perretti,et al.  Immune resolution mechanisms in inflammatory arthritis , 2017, Nature Reviews Rheumatology.

[35]  J. Hellman,et al.  Potentiation and tolerance of toll‐like receptor priming in human endothelial cells , 2017, Translational research : the journal of laboratory and clinical medicine.

[36]  S. Dakin,et al.  Persistent stromal fibroblast activation is present in chronic tendinopathy , 2017, Arthritis Research & Therapy.

[37]  S. Ghosh,et al.  Molecular mechanisms of innate memory and tolerance to LPS , 2017, Journal of leukocyte biology.

[38]  U. Müller-Ladner,et al.  Rheumatoid synovial fibroblasts differentiate into distinct subsets in the presence of cytokines and cartilage , 2016, Arthritis Research & Therapy.

[39]  Alan D. Lopez,et al.  Dissonant health transition in the states of Mexico, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2016, The Lancet.

[40]  F. Berenbaum,et al.  The danger from within: alarmins in arthritis , 2016, Nature Reviews Rheumatology.

[41]  R. Gay,et al.  MicroRNAs interfere with DNA methylation in rheumatoid arthritis synovial fibroblasts , 2016, RMD Open.

[42]  M. Perretti,et al.  Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation , 2016, The Journal of Immunology.

[43]  E. Schwarz,et al.  Lymphatic imaging to assess rheumatoid flare: mechanistic insights and biomarker potential , 2016, Arthritis Research & Therapy.

[44]  E. Latz,et al.  HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins , 2016, Cellular & Molecular Immunology.

[45]  G. Burmester,et al.  Targeting GM-CSF in rheumatoid arthritis. , 2016, Clinical and experimental rheumatology.

[46]  C. Serhan,et al.  Macrophage Proresolving Mediators—the When and Where , 2016, Microbiology spectrum.

[47]  Wei Wang,et al.  LBH Gene Transcription Regulation by the Interplay of an Enhancer Risk Allele and DNA Methylation in Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[48]  D. Irimia,et al.  Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis , 2016, JCI insight.

[49]  A. Bayat,et al.  Epidermal Notch1 recruits RORγ+ group 3 innate lymphoid cells to orchestrate normal skin repair , 2016, Nature Communications.

[50]  Derek W. Gilroy,et al.  Resolution of inflammation: a new therapeutic frontier , 2016, Nature Reviews Drug Discovery.

[51]  T. Wynn,et al.  Macrophages in Tissue Repair, Regeneration, and Fibrosis. , 2016, Immunity.

[52]  F. Dell’Accio,et al.  Neutrophil-derived microvesicles enter cartilage and protect the joint in inflammatory arthritis , 2015, Science Translational Medicine.

[53]  Udo Oppermann,et al.  Inflammation activation and resolution in human tendon disease , 2015, Science Translational Medicine.

[54]  F. Ginhoux,et al.  Ontogeny of Tissue-Resident Macrophages , 2015, Front. Immunol..

[55]  K. Leung,et al.  LXA4 actions direct fibroblast function and wound closure. , 2015, Biochemical and biophysical research communications.

[56]  G. Girolomoni,et al.  Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). , 2015, Journal of the American Academy of Dermatology.

[57]  E. Lubberts,et al.  The IL-23–IL-17 axis in inflammatory arthritis , 2015, Nature Reviews Rheumatology.

[58]  Dan J Stein,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[59]  Timothy J Keyes,et al.  Structural and functional features of central nervous system lymphatics , 2015, Nature.

[60]  C. Buckley,et al.  New pathogenic insights into rheumatoid arthritis , 2015, Current opinion in rheumatology.

[61]  J. Caamaño,et al.  Stromal cells in chronic inflammation and tertiary lymphoid organ formation. , 2015, Annual review of immunology.

[62]  L. Ivashkiv,et al.  Prolonged Tumor Necrosis Factor α Primes Fibroblast‐like Synoviocytes in a Gene‐Specific Manner by Altering Chromatin , 2015, Arthritis & rheumatology.

[63]  G. Haines,et al.  Nonclassical Ly6C(-) monocytes drive the development of inflammatory arthritis in mice. , 2014, Cell reports.

[64]  Juan Li,et al.  Podoplanin: a novel regulator of tumor invasion and metastasis , 2014, Medical Oncology.

[65]  Rikesh Patel,et al.  Stroma: fertile soil for inflammation. , 2014, Best practice & research. Clinical rheumatology.

[66]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[67]  S. Goerdt,et al.  Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.

[68]  G. Randolph,et al.  Origin and functions of tissue macrophages. , 2014, Immunity.

[69]  Charles N. Serhan,et al.  Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.

[70]  K. Alitalo,et al.  Lymphangiogenic factors, mechanisms, and applications. , 2014, The Journal of clinical investigation.

[71]  I. Samokhvalov.  Deconvoluting the ontogeny of hematopoietic stem cells , 2014, Cellular and Molecular Life Sciences.

[72]  B. Shen,et al.  A Novel p53/microRNA‐22/Cyr61 Axis in Synovial Cells Regulates Inflammation in Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[73]  I. González-Álvaro,et al.  IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. , 2013, Rheumatology.

[74]  Bernard Malissen,et al.  Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF , 2013, The Journal of experimental medicine.

[75]  F. Ginhoux,et al.  Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. , 2013, Immunity.

[76]  P. Taylor,et al.  Tissue-resident macrophages , 2013, Nature Immunology.

[77]  A. Filer.  The fibroblast as a therapeutic target in rheumatoid arthritis. , 2013, Current opinion in pharmacology.

[78]  P. Taylor,et al.  Distinct bone marrow-derived and tissue resident macrophage-lineages proliferate at key stages during inflammation , 2013, Nature Communications.

[79]  J. Isaacs,et al.  What can rheumatologists learn from translational cancer therapy? , 2013, Arthritis Research & Therapy.

[80]  F. Ginhoux,et al.  Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. , 2013, Immunity.

[81]  L. Ivashkiv,et al.  Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts. , 2013, Arthritis and rheumatism.

[82]  Stig Peter Magnusson,et al.  Lack of tissue renewal in human adult Achilles tendon is revealed by nuclear bomb 14C , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[83]  J. Liao.  Linking endothelial dysfunction with endothelial cell activation. , 2013, The Journal of clinical investigation.

[84]  A. Mildner,et al.  Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. , 2013, Immunity.

[85]  Ira Tabas,et al.  Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities , 2013, Science.

[86]  S. Pfeffer,et al.  MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes , 2012, Annals of the rheumatic diseases.

[87]  J. Kremer,et al.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. , 2012, The New England journal of medicine.

[88]  T. Mcclanahan,et al.  IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells , 2012, Nature Medicine.

[89]  A. Grobbelaar,et al.  A Review of Fetal Scarless Healing , 2012, ISRN dermatology.

[90]  J. Pollard,et al.  A Lineage of Myeloid Cells Independent of Myb and Hematopoietic Stem Cells , 2012, Science.

[91]  C. Bombardier,et al.  Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative , 2012, Rheumatology.

[92]  R. Leurs,et al.  Pharmacological modulation of chemokine receptor function , 2012, British journal of pharmacology.

[93]  A. Filer,et al.  Fibroblasts as therapeutic targets in rheumatoid arthritis and cancer. , 2012, Swiss medical weekly.

[94]  P. Kalinski.  Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.

[95]  Ruth C Lovering,et al.  Transcriptomic analyses of murine resolution-phase macrophages. , 2011, Blood.

[96]  K. Alitalo,et al.  The lymphatic vasculature in disease , 2011, Nature Medicine.

[97]  B. Nair,et al.  Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells , 2011, Breast Cancer Research.

[98]  D. Veale,et al.  Macrophages in Synovial Inflammation , 2011, Front. Immun..

[99]  P. Tak,et al.  Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? , 2011, Autoimmunity reviews.

[100]  C. Buckley.  Why does chronic inflammation persist: An unexpected role for fibroblasts. , 2011, Immunology letters.

[101]  F. Magrini,et al.  Extended Report , 2011 .

[102]  Soo Young Lee,et al.  Cadherin-11 regulates fibroblast inflammation , 2011, Proceedings of the National Academy of Sciences.

[103]  P. Tak,et al.  Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. , 2011, Arthritis and rheumatism.

[104]  F. Ginhoux,et al.  Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages , 2010, Science.

[105]  M. Genovese,et al.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. , 2010, The New England journal of medicine.

[106]  Quan Zhou,et al.  Near-infrared lymphatic imaging demonstrates the dynamics of lymph flow and lymphangiogenesis during the acute versus chronic phases of arthritis in mice. , 2010, Arthritis and rheumatism.

[107]  E. Middelkoop,et al.  Wound healing in a fetal, adult, and scar tissue model: A comparative study , 2010, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[108]  R. Gay,et al.  DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. , 2009, Arthritis and rheumatism.

[109]  P. Robbins,et al.  Synovial fibroblasts spread rheumatoid arthritis to unaffected joints , 2009, Nature Medicine.

[110]  R. Krumlauf,et al.  Hox genes and segmentation of the hindbrain and axial skeleton. , 2009, Annual review of cell and developmental biology.

[111]  I. Wicks,et al.  G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis , 2009, Nature Reviews Rheumatology.

[112]  E. Middelkoop,et al.  Comparison between human fetal and adult skin , 2009, Archives of Dermatological Research.

[113]  L. Šenolt.  Faculty Opinions recommendation of The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009 .

[114]  M. Kashiwagi,et al.  Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease , 2009, Nature Medicine.

[115]  David Gruben,et al.  The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. , 2009, Arthritis and rheumatism.

[116]  R. Kalluri,et al.  Tumor stroma derived biomarkers in cancer , 2009, Cancer and Metastasis Reviews.

[117]  C. Serhan,et al.  Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions , 2009, The Journal of experimental medicine.

[118]  Andrew Filer,et al.  Fibroblasts from different sites may promote or inhibit recruitment of flowing lymphocytes by endothelial cells , 2009, European journal of immunology.

[119]  Kazuhiko Yamamoto,et al.  Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy , 2008, Modern rheumatology.

[120]  M. Weinblatt,et al.  Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. , 2008, Arthritis and rheumatism.

[121]  C. Serhan,et al.  Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[122]  M. Genovese,et al.  Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. , 2008, Arthritis and rheumatism.

[123]  E. Ekland,et al.  Fibroblast-Type Reticular Stromal Cells Regulate the Lymph Node Vasculature1 , 2008, The Journal of Immunology.

[124]  S. Nicoll,et al.  Fetal ACL Fibroblasts Exhibit Enhanced Cellular Properties Compared with Adults , 2008, Clinical orthopaedics and related research.

[125]  J. Kremer,et al.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.

[126]  U. Andersson,et al.  High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease , 2008, Arthritis research & therapy.

[127]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[128]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[129]  Jordan S. Pober,et al.  Evolving functions of endothelial cells in inflammation , 2007, Nature Reviews Immunology.

[130]  D. M. van der Heijde,et al.  Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.

[131]  T. Lawrence,et al.  Granulocyte-Macrophage Colony-Stimulating Factor (CSF) and Macrophage CSF-Dependent Macrophage Phenotypes Display Differences in Cytokine Profiles and Transcription Factor Activities: Implications for CSF Blockade in Inflammation1 , 2007, The Journal of Immunology.

[132]  M. Salmon,et al.  Targeting stromal cells in chronic inflammation. , 2007, Discovery medicine.

[133]  U. Müller-Ladner,et al.  Microarrays demystified. , 2004, Environmental health perspectives.

[134]  D. Littman,et al.  The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.

[135]  J. Lord,et al.  Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils. , 2006, Arthritis and rheumatism.

[136]  Marek Bogacki,et al.  Scarless skin repair in immunodeficient mice , 2006, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[137]  C. Serhan,et al.  Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. , 2006, The Journal of Immunology.

[138]  G. Bazzoni.  Endothelial tight junctions: permeable barriers of the vessel wall , 2005, Thrombosis and Haemostasis.

[139]  R. Rau,et al.  Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[140]  D. Gilroy,et al.  Aspirin and steroids: new mechanistic findings and avenues for drug discovery. , 2005, Current opinion in pharmacology.

[141]  M. Salmon,et al.  A stromal address code defined by fibroblasts. , 2005, Trends in immunology.

[142]  M. Salmon,et al.  A Chemokine-Dependent Stromal Induction Mechanism for Aberrant Lymphocyte Accumulation and Compromised Lymphatic Return in Rheumatoid Arthritis , 2005, The Journal of Immunology.

[143]  C. Buckley,et al.  The local physicochemical environment conditions the proinflammatory response of endothelial cells and thus modulates leukocyte recruitment , 2004, FEBS letters.

[144]  E. Keystone,et al.  Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.

[145]  Adriano G. Rossi,et al.  Inflammatory Resolution: new opportunities for drug discovery , 2004, Nature Reviews Drug Discovery.

[146]  G. Lisignoli,et al.  CXCL12 chemokine up‐regulates bone resorption and MMP‐9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients , 2004, Journal of cellular physiology.

[147]  M. Dougados,et al.  Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed , 2004, Annals of the rheumatic diseases.

[148]  C. Serhan,et al.  Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. , 2004, Prostaglandins & other lipid mediators.

[149]  F. Amalric,et al.  Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky , 2004, Arthritis research & therapy.

[150]  R. Kalluri,et al.  Epithelial-mesenchymal transition and its implications for fibrosis. , 2003, The Journal of clinical investigation.

[151]  M. Salmon,et al.  Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue. , 2003, Arthritis and rheumatism.

[152]  A. Vallejo,et al.  Synoviocyte-Mediated Expansion of Inflammatory T Cells in Rheumatoid Synovitis Is Dependent on CD47-Thrombospondin 1 Interaction1 , 2003, The Journal of Immunology.

[153]  G. Haines,et al.  IL-6 and Matrix Metalloproteinase-1 Are Regulated by the Cyclin-Dependent Kinase Inhibitor p21 in Synovial Fibroblasts1 , 2003, The Journal of Immunology.

[154]  David Botstein,et al.  Diversity, topographic differentiation, and positional memory in human fibroblasts , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[155]  E. Neilson,et al.  Evidence that fibroblasts derive from epithelium during tissue fibrosis. , 2002, The Journal of clinical investigation.

[156]  E. Bertini,et al.  Collagen VI deficiency affects the organization of fibronectin in the extracellular matrix of cultured fibroblasts. , 2001, Matrix biology : journal of the International Society for Matrix Biology.

[157]  A. Cowin,et al.  Expression of TGF-beta and its receptors in murine fetal and adult dermal wounds. , 2001, European journal of dermatology : EJD.

[158]  G. FitzGerald,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[159]  R. Bucala,et al.  Peripheral Blood Fibrocytes: Differentiation Pathway and Migration to Wound Sites1 , 2001, The Journal of Immunology.

[160]  J. Lord,et al.  Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. , 2001, Trends in immunology.

[161]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[162]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[163]  Frank Emmrich,et al.  Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture — primary culture cells markedly differ from fourth-passage cells , 2000, Arthritis research.

[164]  J. Lord,et al.  Persistent Induction of the Chemokine Receptor CXCR4 by TGF-β1 on Synovial T Cells Contributes to Their Accumulation Within the Rheumatoid Synovium1 , 2000, The Journal of Immunology.

[165]  P. Brenchley.  Angiogenesis in inflammatory joint disease: a target for therapeutic intervention , 2000, Clinical and experimental immunology.

[166]  M. Boers.  Immunohistochemical analysis of vascular endothelial growth factor expression in severe and destructive rheumatoid arthritis. , 2000 .

[167]  H. Genant,et al.  A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. , 2000, Arthritis and rheumatism.

[168]  D. Gilroy,et al.  Inducible cyclooxygenase may have anti-inflammatory properties , 1999, Nature Medicine.

[169]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[170]  Z Domljan,et al.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.

[171]  B. Wolff,et al.  Endothelial Cell “Memory” of Inflammatory Stimulation: Human Venular Endothelial Cells Store Interleukin 8 in Weibel-Palade Bodies , 1998, The Journal of experimental medicine.

[172]  M. Ferguson,et al.  Endogenous inflammatory response to dermal wound healing in the fetal and adult mouse , 1998, Developmental dynamics : an official publication of the American Association of Anatomists.

[173]  P. Gøtzsche,et al.  Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis , 1998, BMJ.

[174]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[175]  D. Willoughby,et al.  The codependence of angiogenesis and chronic inflammation , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[176]  S. Werner,et al.  Transforming Growth Factors 1, 2, and 3 and Their Receptors Are Differentially Regulated during Normal and Impaired Wound Healing (*) , 1996, The Journal of Biological Chemistry.

[177]  T. Springer,et al.  High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. , 1995, Immunology today.

[178]  R. Krumlauf.  Hox genes in vertebrate development , 1994, Cell.

[179]  Motoharu Seiki,et al.  A matrix metalloproteinase expressed on the surface of invasive tumour cells , 1994, Nature.

[180]  S. Gordon,et al.  Macrophage recruitment during limb development and wound healing in the embryonic and foetal mouse. , 1994, Journal of cell science.

[181]  S. Goerdt,et al.  Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. , 1994, Arthritis and rheumatism.

[182]  R. Burgeson,et al.  Cellular origin of the dermal‐epidermal basement membrane , 1993, Developmental dynamics : an official publication of the American Association of Anatomists.

[183]  B. Hazleman,et al.  The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. , 1993, Arthritis and rheumatism.

[184]  G. Haines,et al.  Adhesion molecule expression in human synovial tissue. , 1993, Arthritis and rheumatism.

[185]  G. Huet,et al.  Measurement of elastase and cysteine proteinases in synovial fluid of patients with rheumatoid arthritis, sero-negative spondylarthropathies, and osteoarthritis. , 1992, Clinical chemistry.

[186]  M. Ferguson,et al.  Immunohistochemical localization of growth factors in fetal wound healing. , 1991, Developmental biology.

[187]  M. Hamberg,et al.  Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[188]  D. Tarin,et al.  The influence upon wound contraction of a negative interstitial fluid pressure within granulation tissue. , 1969 .

[189]  F. Vanaclocha,et al.  Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate‐to‐severe plaque psoriasis up to 1 year: Results from the CLEAR study , 2017, Journal of the American Academy of Dermatology.

[190]  E. Latz,et al.  HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins , 2017 .

[191]  A. Roberts,et al.  Targeting GM-CSF in inflammatory diseases , 2016, Nature Reviews Rheumatology.

[192]  K. Ley,et al.  Leucocyte-endothelial interactions in health and disease. , 2006, Handbook of experimental pharmacology.

[193]  M. Pillinger,et al.  The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases. , 2006, Bulletin of the NYU hospital for joint diseases.

[194]  M. Gaudry,et al.  Immunohistochemical analysis of vascular endothelial growth factor expression in severe and destructive rheumatoid arthritis. , 2000, The Journal of rheumatology.

[195]  B. Levy,et al.  Lipoxins, aspirin-triggered 15-epi-lipoxin stable analogs and their receptors in anti-inflammation: a window for therapeutic opportunity. , 2000, Ernst Schering Research Foundation workshop.

[196]  G R Burmester,et al.  Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? , 1997, Arthritis and rheumatism.

[197]  S. Werner,et al.  Transforming growth factors beta1, beta2, and beta3 and their receptors are differentially regulated during normal and impaired wound healing. , 1996, The Journal of biological chemistry.

[198]  D. Haskard,et al.  Expression of vascular cell adhesion molecule-1 in normal and inflamed synovium. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[199]  R. Akhurst,et al.  Rapid induction and clearance of TGF beta 1 is an early response to wounding in the mouse embryo. , 1993, Developmental genetics.

[200]  Evon M. O. Abu-Taieh,et al.  Comparative Study , 2020, Definitions.

[201]  D. Tarin,et al.  Ultrastructural features of wound healing in mouse skin. , 1969, Journal of anatomy.